Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Good News for Patients Is Lifting These 2 Biopharma Stocks: https://g.foolcdn.com/editorial/images/730733/biotech-scientist-microscope-getty.jpg
Good News for Patients Is Lifting These 2 Biopharma Stocks

Overall, the stock market is facing a serious case of the jitters on Wednesday morning, as investors wait anxiously for the coming decision on interest rates from the Federal Reserve later this

TheMotleyFool 
0 03.05.23
Why Pfizer Is Among the Best High-Yield Dividend Stocks on the Market Now: https://g.foolcdn.com/editorial/images/730554/scientists-monitor-showing-virus.jpg
Why Pfizer Is Among the Best High-Yield Dividend Stocks on the Market Now

Some income investors might view Pfizer (NYSE: PFE) stock as a falling knife to be avoided. After all, the big drugmaker's share price has already plunged more than 20% so far this year. Pfizer just

TheMotleyFool 
0 03.05.23
7 Reasons to Buy Vertex Pharmaceuticals Stock Now: https://g.foolcdn.com/editorial/images/730532/scientists-in-a-lab.jpg
7 Reasons to Buy Vertex Pharmaceuticals Stock Now

Another quarter, another solid performance from Vertex Pharmaceuticals (NASDAQ: VRTX). The big drugmaker beat consensus estimates for its Q1 results announced on Monday. Vertex's shares subsequently

TheMotleyFool 
0 03.05.23
Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis: https://mms.businesswire.com/media/20230501005338/en/1647007/5/Almirall_HQ_in_Barcelona.jpg
Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis


Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks

BusinessWire_EN 
0 03.05.23
EQS-News: Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS): https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
EQS-News: Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
eqs_en 
0 03.05.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
eqs_en 
0 02.05.23
EQS-News: Newron announces Senior Management Team changes: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron announces Senior Management Team changes
EQS-News: Newron announces Senior Management Team changes
eqs_en 
0 02.05.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
eqs_en 
0 01.05.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 28.04.23
EQS-Adhoc: Biotest AG: Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
EQS-Adhoc: Biotest AG: Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised
EQS-Adhoc: Biotest AG: Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised
eqs_en 
0 28.04.23
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
eqs_en 
0 27.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 27.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 26.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 25.04.23
EQS-News: Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
EQS-News: Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary
EQS-News: Biotest AG: Biotest AG opens 12th plasma collection centre in Hungary
eqs_en 
0 25.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 24.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 20.04.23
EQS-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Germany: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
EQS-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Germany
EQS-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Germany
eqs_en 
0 20.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 19.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 18.04.23
EQS-News: Newron announces AGM 2023 results  : https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron announces AGM 2023 results  
EQS-News: Newron announces AGM 2023 results  
eqs_en 
0 18.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 17.04.23
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
eqs_en 
0 16.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 14.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 13.04.23